Pharmacoeconomic evaluation of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia

American Journal of Managed Care

Volumn 2, Issue 8, 1996, Pages 1055-1073

  Kong, Sheldon Xiaodong ^a   Gandhi, Sanjay K ^a   Crawford, Stephanie Y ^a   Seeger, John D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000339086     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Gunby P. Cardiovascular diseases remain nation's leading cause of death. JAMA 1992;267:335-336.
2. Higgins M, Thorn R. Trends in coronary heart disease in the United States. Int J Epidemiol 1989;18(suppl 1):S58-S66.
3. Goldman L, Gorden DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992;85:1960-1968.
4. Reckless JPD. Cost implications of lipid-lowering treatments. PharmacoEconomics 1994;6:310-323.
5. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;322:512-521.
6. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Program Adult Treatment Panel. JAMA 1993; 269:3009-3014.
7. Adult Treatment Panel II. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1329-1445.
8. Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36-69.
9. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D-11D.
10. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-385.
11. Kong SX, Stubbing J. Assessing the economic value of pharmaceutical services and products. J Pharm Prac 1995;8:142-153.
12. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987;107:224-233.
13. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993;71:810-815.
14. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-1414.
15. The Lovastatin Study Group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. Am J Cardiol 1990;66: 22B-30B.
16. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-1037.
17. Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology 1994;85:244-254.
18. Beigel Y, Brook G, Eisenberg S, et al. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: The Israeli experience. Isr J Med Sci 1993;29:272-277.
19. Betteridge DJ, Durrington PN, Fairhurst GJ, et al. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 1994;96:45S-54S.
20. Betteridge DJ, Bhatnager D, Bing RF, et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992;304:1335-1338.
21. Blankenhorn D, Azen S, Kramch D, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
22. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
23. Broyles F, Walden C, Hunninghake D, et al. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 1995;76:129A-135A.
24. Capurso A, Resta F, Bertolini S, et al. Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double- blind placebo-controlled study. Eur Heart J 1992;13(suppl B):11-16.
25. Crepaldi G, Baggio C, Area M, et al. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. Arch Intern Med 1991;151:146-152.
26. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. Am J Cardiol 1992;69:28-34.
27. Farmer JA, Washington LC, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther 1992;14:708-717.
28. Greten H, Beil FU, Schneider J, et al. Treatment of primary hypercholesterolemia: Fluvastatin versus bezafibrate. Am J Med 1994;96:55S-63S.
29. Hoogerbrugge N, Mol MJ, Van Dormaal JJ, et al. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med 1990;228:261-266.
30. Hunninghake DB, Knopp RH, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis 1990;85:81-89.
31. Insull W, Black D, Dujovne C, et al. Efficacy and safety of once-daily vs twice daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hyperchoelsterolemia. Arch Intern Med 1994;154:2449-2455.
32. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacin in hypercholesterolemia: A preliminary report on gender differences in efficacy. Am J Med 1994;96:64S-68S.
33. Jacotot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995;76:54A-56A.
34. Jacotot B, Banga JD, Pfister P, Mehra M. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. Br J Clin Pharmacol 1994;38:257-263.
35. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994;15:255-269.
36. Klausen IC, Gerdes LU, Meinertz H, et al. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. Eur J Clin Invest 1993;23:240-245.
37. Knopp RH, Frohlich J, Jokubaitis LA, et al. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96:69S-78S.
38. Lambrecht LJ, Malini PL. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol 1993;48: 541-554.
39. LaRosa JC, Applegate W, Crouse JR, et al. Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994;154:529-539
40. Leitersdorf E, Eisenberg S, Eliav O, et al. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia. Eur J Clin Pharmacol 1993;45:513-518.
41. Lintott C, Scott R, Bremer J, Shand B. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol 1995;76:97A-101A.
42. McPherson R, Bedard J, Connelly P, et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 1992;14:276-291.
43. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993;13:439-444.
44. Pietro DA, Alexander S, Mantell G, et al. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). Am J Cardiol 1989;63:682-686.
45. Saito Y, Yoshida S, Nakaya N, et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991;11:816-826.
46. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994;96:509-515.
47. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995;333:1301-1307.
48. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994;120:537-543.
49. Tikkanen MJ, Helve E, Jaattelä A, et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish Multicenter Study. Am J Cardiol 1988;62:35J-43J.
50. Tuomilehto J, Guimaraes A, Kettner H, et al. Dose-response of simvastatin in primary hypercholesterolemia. J Cardiovasc Pharmacol 1994;24:941-949.
51. Valles F, Anguita M, Anglada J, et al. A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia. Atherosclerosis 1991;91(suppl):S3-S9.
52. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20.
53. Wiklund O, Angelin B, Fager G, et al. Treatment of familial hypercholesterolaemia: A controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990;228:241-247.
54. Ziegler O, Drouin P. Safety, tolerability, and efficacy of simvastatin and fenofibrate - A multicenter study. Simvastatin-Fenofibrate Study Group. Cardiology 1990;77(suppl 4):50-77.
55. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and choelstyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993;153:1321-1329.
56. MAAS Investigators. Effect of simvastatin on coronary atheroma: The multicenter anti-atheroma study (MAAS). Lancet 1994;344:633-638.
57. Martens LL, Rutten FFH, Erkelens DW, Ascoop CAPL. Cost effectiveness of cholesterol-lowering therapy in Netherlands: Simvastatin versus cholestyramine. Am J Med 1989;87:54S-58S.
58. Martens LL, Rutten FFH, Erkelens DW, Ascoop CAPL. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol 1990;65:27F-32F.
59. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: Cost-effectiveness of pharmacologie management. JAMA 1990;264: 3025-3033.
60. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-1151.
61. Hay JW, Wittels EH, Gotto AM. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991;67:789-796.
62. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine: Results from Sweden. PharmacoEconomics 1992;1:213-216.
63. Lim MCL, Foo WM. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidemia. Ann Acad Med Singapore 1992;21:34-37.
64. Guibert R, Contandriopoulos AP, Champagne F, et al. Cost-effectiveness analysis of lipid modulators in Canada: Results and potential usefulness. Can J Cardiol 1993; 9(suppl D):28D-29D.
65. Goldman L, Goldman PA, Williams LW, et al. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993;72:75D-79D.
66. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994;16:1052-1062.
67. Smart AJ, Walters L. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors. S Afr Med J 1994;84: 834-837.
68. Hamilton VH, Racicot F, Zowall H, et al. The cost-effectiveness of HMG-CoA reductase inhibitors: Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032-1038.
69. Korman L, Borysiuk L. Replacing lovastatin with pravastatin: Effect of serum lipids and costs. Am J Health-Syst Pharm 1995:52:1078-1082.
70. Perderson TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of health resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93: 1796-1802.
71. Oster G, Borok GM, Menzin J, et al. Cholesterol-Reduction Intervention Study (CRIS). A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med 1996;156:731-739.
72. Heudebert GR, Van Ruiswyk J, Hiatt J, et al. Combination drug therapy for hypercholesterolemia. Arch Intern Med 1993;153:1828-1837.
73. Kannel WB, Woolf PA, Garrison RJ, eds. The Framingham Study. An Epidemiological Investigation of Cardiovascular Disease. Washington, DC: United States Government Printing Office; 1987. NIH 87-2703
74. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
75. Krahn M, Gafni A. Discounting in the economic evaluation of health care intervention. Med Care 1993;31:403-418.
76. Eisenberg JM. Clinical economics: A guide to the economic analysis of clinical practices. JAMA 1989;262:2879-2886.
77. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death: The Framingham study. Arch Intern Med 1981;141:1128-1131.
78. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study. JAMA 1986;256:2835-2838.
79. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factors Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
80. Angerson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow up from the Framingham study. JAMA 1987;257:2176-2180.
81. Davidson MH. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Cardiol 1994;96:41S-44S.
82. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Am J Cardiol 1994;74: 667-673.
83. Lovastatin Study Groups I through IV. Lovastatin 5-Year Safety and Efficacy Study. Arch Intern Med 1993;153:1079-1087.
84. Bradford RH, Downton M, Chremos AN, et al. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med 1993;118:850-855.
85. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995,333:1301-1307.
86. Emron HMO Prescription Drug Therapeutic Class Survey. January-June, 1995.